The Australian Competition Authority refuses to give an authorisation for the provisions of a settlement and licence agreement between pharmaceutical companies (Celgene / Juno / Natco)

ACCC not satisfied of claimed benefits from proposed settlement between pharmaceutical companies* The ACCC proposes to deny authorisation for the provisions of a settlement and licence agreement between Celgene and generic drug companies, Juno and Natco. The companies are seeking authorisation to settle a patent dispute currently before the Federal Court of Australia. Given the lack of information provided about the extent of benefits from the agreement, and its impact on competition, the ACCC is not satisfied that the likely public benefits outweigh the likely public detriments. Without authorisation the agreement and related conduct risks breaching the Competition and Consumer Act. Celgene manufactures the drugs Revlimid and Pomalyst (with active ingredients

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Australian Competition Authority, The Australian Competition Authority refuses to give an authorisation for the provisions of a settlement and licence agreement between pharmaceutical companies (Celgene / Juno / Natco), 23 March 2022, e-Competitions March 2022, Art. N° 106014

Visites 299

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues